Figure 3
From: Mass cytometry reveals cladribine-induced resets among innate lymphoid cells in multiple sclerosis
CD38+ but not CD38− NK cells remain unaffected by CladT. (a) Expression levels of CD38 among CD56+CD94+ NK cells on Fast Interpolation-based t-stochastic neighbor embedding (FIt-SNE) plots. A subsample of up to 70,000 cells from all study participants (non-MS controls, MS patients from all timepoints and batch controls) were included for the generation of FIt-SNE plots. (b) CD38+CD56+CD94+, CD38+CD56dim, CD38+CD56bright NK cells as cells/mL in MS patients at baseline (prior, n = 12), and 2 (2M, n = 10), and 6 months (6M, n = 12) following administration of CladT. (c) CD38-CD56+CD94+, CD38−CD56dim and CD38−CD56bright NK cells as cells/mL in MS patients prior (n = 12), 2M (n = 10), and 6M (n = 12) following administration of CladT. (D) CD38 median signal intensity of MS patients at prior (n = 12), 2M (n = 10), and 6M (n = 12) following administration of CladT. A linear mixed-effects model was calculated to compare between MS patients before and after treatment. 4999 permutations were then run to calculate p-values. Holm’s corrections were used for multiple comparisons which were performed to compare the different timepoints (prior, 2M & 6M). p-values of p < 0.1 are indicated on the graphs.
